Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC

Clinical trial NCT04141644 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04141644
Sponsor: University of Utah
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)

Start date: 2020-08-20
Primary completion: 2024-01-29
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.